Beta-lactamases in Enterobacteriaceae - An ever-present threat

South African Medical Journal

Volumn 96, Issue 4, 2006, Pages 331-334

  Moolman, G J J ^a   Jankowitz, C E ^a   Bezuidenhout, S ^a   Pitout, J D D ^b  

^a LANCET LABORATORIES   (South Africa)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CITROBACTER FREUNDII; CITROBACTER KOSERI; ENTEROBACTER; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESCHERICHIA COLI; HAFNIA ALVEI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; KLUYVERA; MORGANELLA MORGANII; NONHUMAN; PHENOTYPE; PROTEUS MIRABILIS; PROTEUS VULGARIS; PROVIDENCIA; SALMONELLA; SERRATIA; SHIGELLA;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; COLONY COUNT, MICROBIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 33645990634     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Livermore DM. Interpretative reading: Recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001; 48: Suppl. S1, 87-102.
2. Livermore DM. β-Lactamases in laboratories and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility tests. Approved Standards. 8th ed. M2-A8; 23 Villanova, Pa, 2003.
4. Pitout JDD, Reisbig MD, Venter EC, et al. Modification of the double-disk test for detection of Enterobacteriaceae producing extended-spectrum and amp C β-lactamases. J Clin Microbiol 2003; 41: 3933-3935.
5. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
6. Espinasse F, Gheorghiu R, Poiata A, et al. Reduced susceptibility to co-amoxiclav in Escherichia coli, Salmonella typhimurium and Klebsiella pneumoniae isolates in Romania between 1985 and 1993. J Antimicrob Chemother 1997; 39: 103-106.
7. Chaibi EB, Sirot D, Paul G, et al. Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447-458.
8. Sirot D, Sirot J, Labia R, et al. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: Identification of CTX-1, a novel beta-lactamase. J Antimicrob Chemother 1987; 20: 323-334.
9. Nordman P.Trends in β-lactam resistance among Enterobacteriaceae.Clin Infect Dis 1998; 27: Suppl 1, S100-106.
10. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-3554.
11. Wiedemann B, Dietz H, Pfeifle D. Induction of β-lactamase in Enterobacter cloacae. Clin Infect Dis 1998; 27: Suppl 1, S42-47.
12. Oliver A, Weigel LM, Rasheed JK, et al. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 2002, 46: 3829-3836.
13. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcome. Clin Infect Dis 2001; 32: 1162-1171.